PIK3CA and neoplasm: In the BOLERO-2 study, mutational analysis of plasma cell-free DNA (cfDNA) indicated no relationship between PFS after everolimus treatment and PIK3CA genotypes, which was consistent with a previous analysis of tumor tissue DNA [14].